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Cancerous lesions promote tumor growth, motility, invasion, and angiogenesis via oncogene-driven immu-
nosuppressive leukocyte infiltrates, mainly myeloid-derived suppressor cells, tumor-associated macro-
phages, and immature dendritic cells (DCs). In addition, many tumors express or induce immunosuppressive
cytokines such as TGF-b and IL-10. As a result, tumor-antigen crosspresentation by DCs induces T cell
anergy or deletion and regulatory T cells instead of antitumor immunity. Tumoricidal effector cells can be
generated after vigorous DC activation by Toll-like receptor ligands or CD40 agonists. However, no single
immunotherapeutic modality is effective in established cancer. Rather, chemotherapies, causing DC activa-
tion, enhanced crosspresentation, lymphodepletion, and reduction of immunosuppressive leukocytes, act
synergistically with vaccines or adoptive T cell transfer. Here, I discuss the considerations for generating
promising therapeutic antitumor vaccines that use DCs.Introduction
Dendritic cells (DCs) play a pivotal role in the initiation, program-
ming, and regulation of tumor-specific immune responses (Stein-
man and Banchereau, 2007; Dhodapkar et al., 2008). Neverthe-
less, surprisingly little is known about the role of different DC
subsets in cancer initiation and progression in patients. Rather,
most of the efforts have been focused on utilization of the immu-
nostimulatory power of fully activated DCs for immunotherapy of
cancer (Figdor et al., 2004; Palucka et al., 2007; Lesterhuis et al.,
2008). Despite this effort, a full understanding of the complex
relations between tumors and the host, including DC-mediated
regulation of host leukocyte responses, is likely to improve the
precision and effectiveness of cancer immunotherapy. It is im-
portant to remember that passive immunotherapy withmonoclo-
nal antibodies is nowaconsiderable successwith great hopes for
the future (Finn, 2008), and effective therapies promoting cell-
mediated anticancer immune responses are likely to follow. In
this review, I will discuss the evidence that cancer is associated
with an environment disfavoring the DC activation required for
proper effector CD4+ and CD8+ T cell activation, including evi-
dence that DC phenotypes in cancer tissue and draining lymph
nodes usually carry an ‘‘immature’’ phenotype and that mye-
loid-derived suppressor cells (MDSCs) and tumor-associated
macrophages (TAMs) adversely affect DC function. I will then
discuss how DC-based immunotherapy can be improved and
emphasize the need for combining antigen-specific DC-based
therapy with other therapies for effective treatment.
Immunosurveillance of Virus-Induced Tumors
Patients with T cell deficiencies or under immunosuppressive
therapy are at an increased risk of virus-induced malignancies,
induced by viruses such as Epstein-Barr Virus (EBV) or high-
risk human papilloma virus (HPV) (Grulich et al., 2007; Angeletti
et al., 2008). Nevertheless up to 15%of cancers in healthy immu-
nocompetent people are also caused by viruses. Interestingly,
those immunocompetent women that do not spontaneously
clear such HPV infections, and are therefore at risk of developing
cervical cancer, fail to generate interferon-g (IFN-g)-producing372 Immunity 29, September 19, 2008 ª2008 Elsevier Inc.T cells to the early viral proteins E2 and E6 (de Jong et al.,
2004; Welters et al., 2006) . This failure of IFN-g production is
HPV specific. Most infected women succeed, however, in clear-
ing high-risk HPV infections by effective IFN-g T cell responses
(de Jong et al., 2004; Welters et al., 2006). Both high-risk HPV
DNA, through CpG motifs triggering TLR9 (Hasan et al., 2007),
as well as the viral capsid protein L1 (Lenz et al., 2001; Da Silva
et al., 2007) possess DC-activating ability, thereby explaining the
induction of robust T cell responses and viral clearance in the
majority of people. Nevertheless, in a minority of women the
virus, presumably aided by its capacity to downregulate type I
IFN responses, persists and transforms keratinocytes (Nees
et al., 2001), thereby avoiding DC activation by type I IFN. Fur-
ther, keratinocytes transformed by high-risk HPV do not express
TLR9 (Hasan et al., 2007), in contrast to normal differentiated
keratinocytes; such a result ensures the lack of production of
DC activating signals by the transformed cells through this path-
way. This example illustrates the subtlety of the balance between
virus and host: Virus control is the rule and oncogenesis the
exception, at least in immunocompetent individuals. A similar
subtlety seems to apply to nonviral cancers as exemplified by
chemical carcinogenesis. Clearly, the adaptive T cell response
cannot prevent chemical carcinogenesis, but tumor dormancy
in a chemical carcinogenesis model is clearly kept in check by
IFN-g-dependent T cell immunity (Koebel et al., 2007), indicating
that sufficient DC activation occurred spontaneously in this
model to induce effector T cells with antitumor activity.
Cancer Associated with Chronic Inflammation
Chronic inflammation is considered to contribute to the develop-
ment of 15%–20% of malignancies worldwide, including
esophageal, gastric, hepatic, pancreatic, and colorectal cancer
(Mantovani and Pierotti, 2008). Inflammatory bowel disease is
a known condition predisposing to colorectal cancer (Konda
and Duffy, 2008; Atreya and Neurath, 2008). In addition, long-
term use of nonsteroidal anti-inflammatory drugs such as aspirin
is known to reduce the risk of colorectal cancer development
(Wang and Dubois, 2008). Inflammatory mediators can also be
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and by cells in the (pre-)malignant stroma, including leukocyte
populations, in particular the MDSCs (Marigo et al., 2008) and
TAMs (Sica and Bronte, 2007) (Figure 1), mainly under the influ-
ence of activated cellular oncogenes such as MYC, RAS, RET,
and BRAF (Borrello et al., 2008).These mediators can cause leu-
kocyte recruitment (Sica and Bronte, 2007; Marigo et al., 2008)
and angiogenesis and can influence tumor cell survival, motility,
and chemotaxis.(Borrello et al., 2008).
The well-known transcription factor NF-kB plays a particularly
important role in liver cell homeostasis, cell survival, and carcino-
genesis (Vainer et al., 2008) and is pivotal in the activation of DCs
by a variety of stimuli. In some liver cancer models in mice,
NF-kB expression in liver cells promotes cancer, whereas in
other models, it impedes carcinogenesis (Vainer et al., 2008).
Furthermore, breast cancer cells are known to produce the
inflammatory chemokines CCL2 and CCL5, which are poorly
expressed by normal breast cells (Soria and Ben-Baruch,
2008). These chemokines mediate a shift in the balance between
different stromal leukocyte populations in favor of deleterious
TAMs and inhibit potential antitumor T cells (Soria and Ben-Bar-
uch, 2008). CCL2 also promotes angiogenesis. In addition, both
chemokines act directly on the tumor cells and increase their
migratory and invasion-related phenotype (Soria and Ben-
Baruch, 2008).
Figure 1. Subversion of Effector T Cell Responses by Cancerous
Growth
Oncogenic protein expression in cancer cells causes overexpression of
STAT3, production of CCL2, CCL5, and CXC chemokines, and production of
IL-10 or TGF-b cytokines. Together, these factors attract tumor-associated
macrophages (TAMs) and myeloid derived suppressor sells (MDSCs) into
the tumor stroma. As a result, resting tumor-associated and tumor-draining
lymph-node-resident DCs are insufficiently activated and improperly polar-
ized. This leads to the generation in the lymph node of anergic T cells and
Treg cells. An unknown proportion of tumor-responding T cells may also be
deleted. The abnormal tumor vasculature hinders the smooth entry of
tumor-specific effector cells into vascularized cancer nodules.Last but not least, a prominent feature of many cancer cells is
constitutive oncogene- and cytokine-driven overexpression of
the STAT3 protein (Wang et al., 2004; Kortylewski et al., 2005;
Kortylewski and Yu, 2008) (Figure 1). STAT3 upregulates the
expression of several immunosuppressive cytokines, including
IL-10 and TGF-b, and suppresses T helper 1 (Th1) cell immune
responses (Kortylewski et al., 2005; Kortylewski and Yu, 2008).
STAT3 expression by tumor cells begets STAT3 production by
a variety of leukocytes, including DCs, interacting with the tumor
cells, with wide-ranging deleterious effects on antitumor effector
leukocytes (Kortylewski and Yu, 2008). In particular, STAT3 ex-
pression in tumor-associated DCs causes reduced expression
of costimulatory molecules and MHC class II (Kortylewski and
Yu, 2008), as well as production of TGF-b (Kortylewski and Yu,
2008). Tumor progression indeed correlates with an accumula-
tion of immature DCs that induce the expansion of regulatory T
(Treg) cells in tumor-draining lymph nodes (Ghiringhelli et al.,
2005).The STAT3 inhibitor Cucurbitacin I specifically decreases
the amounts of phosphorylated STAT3 (P-STAT3) in many
mouse and human cancer cell lines (Blaskovich et al., 2003;
Shi et al., 2006b; van Kester et al., 2008) and inhibits the growth
of tumors in mice (Blaskovich et al., 2003). In cutaneous T cell
lymphomas, including Sezary syndrome, Cucurbitacin I also
inhibited P-STAT3 and caused tumor cell apoptosis in vitro
(van Kester et al., 2008). This inhibitor thus could help to not
only directly kill tumor cells but also redress the immunosuppres-
sion associated with P-STAT3 signaling.
DC Numbers and Phenotypes in Cancer
DC phenotypes in cancer tissue and cancer-draining lymph
nodes are often those corresponding to resting, nonactivated,
‘‘immature’’ DCs, both in tumor-bearing animals and in patients
with cancer (reviewed in Gabrilovich, 2004; Schuurhuis et al.,
2006a; Dhodapkar et al., 2008) (vanMierlo et al., 2004; Boonman
et al., 2005) Early studies have suggested that patients with high
numbers of DCs present in tumors survived longer than patients
with few or no DCs in the cancer tissue (Becker, 1993). However,
in a more recent study, colorectal cancer patients with relatively
high numbers of ‘‘mature’’ CD208+-infiltrating DCs in the tumor
epithelium had a markedly shorter survival rate (Sandel et al.,
2005). In addition, patients with relatively high numbers of
CD1a+ DCs in the advancing margin of the tumor had amarkedly
shorter disease-free survival rate (Sandel et al., 2005). In the case
of human breast cancer, infiltration of cancer tissue with mature
DCs is frequently seen, but these DCs drive a CD4+ T cell re-
sponse associated with secretion of IL-13, thereby facilitating
tumor growth rather than inhibition, which explains the eosino-
phil granulocyte infiltrations often seen in breast cancer tissue
(Aspord et al., 2007). In contrast, in a cohort of 39 patients with
advanced melanoma (stages III B or C and IV), treated with the
cytokine GM-CSF, a greater increase in mature DCs after treat-
ment was associated with disease remission or delayed recur-
rence (Daud et al., 2008). The immunosuppressivemilieu created
by cancers generally causes a decrease in the numbers of con-
ventional ‘‘myeloid’’ DCs, with little or no effects on the numbers
of plasmacytoid DCs (Gabrilovich, 2004). Thus, immature mye-
loid DCs promote the expansion of Treg cells in tumor-draining
lymph nodes, associated with tumor progression in a TGF-b-
dependent fashion (Ghiringhelli et al., 2005). However, theseImmunity 29, September 19, 2008 ª2008 Elsevier Inc. 373
Immunity
Reviewfindings were made in rodent models. In general, it is safe to as-
sume that neither the decreased numbers of immature myeloid
DCs found in human cancers nor the immature pDCs contribute
to immune defenses against these cancers, but more work is
required to chart the clinical significance of the different human
cancer-associated DC populations. Even if these improperly
activated or even dysfunctional tumor-associated DCs support
immune responses compatible with oncogenesis or even pro-
mote oncogenesis, therapeutic activity can be imprinted in these
DCs by molecularly defined triggers of DC maturation causing
induction of robust tumor-specific effector T cells, as discussed
below.
Suppression of DC Function in the Tumor Environment
The inflammatory nature ofmany cancers and the resulting tumor
infiltrationwith assorted leukocytes, in particularmyeloidMDSCs
andTAMs (Sica andBronte, 2007;Marigo et al., 2008), creates an
immunosuppressive environment that leads to suppression of
DC-instructed effector CD4+ and CD8+ T cell responses and
the induction of Treg cells. Much of this immunosuppression is
mediated by cytokines secreted by the tumor or the tumor-infil-
trating MDSCs and/or TAMs acting on the DCs in the draining
lymphnodespresenting tumor-associated antigens (Gabrilovich,
2004). In addition, direct chemical and enzymatic interactions
between leukocyte products and tumor-responding T cells,
such as nitrotyrosination of the T cell receptor (TCR) and CD8
molecules, have been described (Nagaraj and Gabrilovich,
2008). The relative importance of direct deleterious effects
exerted by tumor-associatedMDSCsandTAMsonT cells versus
effects exerted onmigratory DCs from tumors and DCs in tumor-
draining lymph nodes is not known. Nevertheless, the end result
is immunosuppression of tumor-directed T cell responses. It is
likely that both mechanisms operate in a tumor setting. Further
dissection of these complicated mechanisms is likely to yield
new therapeutic possibilities. In a study of sporadic tumorigene-
sis by anSV40 large Toncogene inmice, the prominent induction
of MDSCswith deviation and suppression of the anti-SV 40 T cell
responses was shown to be associated with tumor outgrowth
(Willimsky et al., 2008). However, the interpretation that this
model is a reflection of the general absence of immunoediting
and immunosurveillance against sporadic nonviral tumors is
probably premature. More likely, the balance between immuno-
suppression and immunosurveillance exerted by spontaneously
arising tumors varies depending on the inflammatory signature
installedby thedistinctive oncogenic events in each tumor or pre-
malignant lesion. In the case of SV 40 large T, powerful inflamma-
tory abnormalities could have been caused in the premalignant
and malignant stages, which are not generally representative of
other tumormodelsor humancancer. Also, theevidence fromdif-
ferent tumor models is overwhelming that the lack of T cell effec-
tor function, apart from the suppressive effects ofMDSCs, TAMs,
and Foxp3+ Treg cells, is caused by lack of expression of costi-
mulatory molecules on tumor-associated DCs or by dysregula-
tion of costimulatory pathways (Kortylewski and Yu, 2008; Keir
et al., 2008). In the case of SV40 oncogenesis, this situation can
be addressed therapeutically as illustrated in a nonsporadic
model of tumorigenesis by SV40 large T (expressed under the
rat insulin promoter), in which tumor-specific CD8+ T cells were
not ablated by the insufficiently activated DC, but could be374 Immunity 29, September 19, 2008 ª2008 Elsevier Inc.aroused to full effector function, associated with a greatly en-
hanced lifespan of the tumor-bearing mice by intravenous vacci-
nation with tumor-derived peptide and agonistic DC-activating
CD40 antibody or DC-activating viral immunization and boosting
(Nguyen et al., 2002).
Mechanisms of Crosspresentation for CD8+ T Cell
Recognition of Tumor Antigens
DCs can present antigens to CD8+ T cells either through endog-
enous processing after, e.g., microbial infection or by uptake and
processing of exogenous antigens, a process known as cross-
presentation. Both modes of antigen presentation probably
play a role in infectious disease (Melief, 2003; van der Bruggen
and Van den Eynde, 2006; Lin et al., 2008b), but in the case of
cancer, crosspresentation after uptake andprocessing of soluble
or particulate matter from apoptotic, necrotic cancer or even live
cancer cells is the only important natural mode of presentation
(Melief, 2003; Gabrilovich, 2004; van der Bruggen and Van den
Eynde, 2006; Lin et al., 2008b). Our knowledge of mechanisms
operating in the ingestion, processing, and, ultimately, crosspre-
sentation of tumor-associated antigens to CD8+ T cells by DCs is
mainly derived from in vitro experiments. Clearly, a variety of
mechanisms can transfer antigens from tumors to DCs for
MHC class I presentation, including: (1) antigens from dead cells
(apoptotic or necrotic tumor cells) (Albert et al., 1998; Blachere
et al., 2005; Berg et al., 2006; Fonseca andDranoff, 2008), (2) sol-
uble antigens bound to chaperonins such as heat shock proteins,
docking onto scavenger receptors on DCs (Binder et al., 2007;
Giodini and Cresswell, 2008), (3) soluble proteins (Norbury
et al., 2004), (4) antigen-carrying vesicles secreted by some tu-
mor cells, called exosomes (Zeelenberg et al., 2008), (5) transfer
of small antigenic protein fragments through so-called gap junc-
tions (Neijssen et al., 2005), (6) plasma-membrane fragments
‘‘nibbled’’ from live tumor cells by DCs (Harshyne et al., 2001),
and (7) an apparently unrelated mechanism called ‘‘crossdress-
ing’’: Peptide-MHC class I complexes are acquired by direct
contact of DCs with dead, but not live, tumor cells (Dolan et al.,
2006). Mechanisms 6 and 7, in contrast to the others listed, oper-
ate in the absence of antigen processing by the DC and involve
direct transfer of peptide-MHC complexes to the DC. This last
mechanism also seems to operate in vivo in influenza virus infec-
tion, in that TAP-deficient DCs acquired influenza peptide-
MHC class I complexes from apoptotic influenza-infected cells
(Blachere et al., 2005).
The rules and mechanisms are much less known for crosspre-
sentation of tumor-associated antigens in vivo. It seems reason-
able, however, to rely in large part on the general rules for in vivo
crosspresentation delineated fromwork outside the cancer field.
In mouse experiments with the model antigen ovalbumin (Ova),
low expression of Ova is associated with the lack of crosspre-
sentation, whereas high expression of Ova is associated with
crosspresentation and, in the absence of DC activation, with
peripheral deletion of Ova-specific T cells (Kurts et al., 1999).
The amount of antigen expression is therefore very important
for crosspresentation to CD8+ T cells.
In another study with DNA vaccines, the stability of the protein
expressed from the DNA used for vaccination is also important
for immunogenicity, in the sense that high protein stability corre-
sponds to high immunogenicity (Bins et al., 2007). High protein
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delivery of DNA encoding the tumor-associated antigen HPV 16
E7, a vaccine delivery method inducing robust CD8+ cytotoxic T
lymphocyte (CTL) responses, again consistent with the notion
that high protein expression promotes crosspresentation to
CD8+ T cells (Bins et al., 2005). In mice deficient for the GTPase
Rac1, crosspresentation is severely disturbed, causing lack of
T cell tolerance for self tissues, indicating that self-tolerance de-
pends on crosspresentation to CD8+ CTL precursors of normal
tissue antigens, probably from natural tissue apoptosis (Lucka-
shenak et al., 2008). Thus, high amounts and stable protein
expression by tumors, as well as a high degree of spontaneous
tumor apoptosis or necrosis that releases high amounts of
proteins, favor crosspresentation.
Crosspresentation of Tumor-Associated Antigens
by DCs in Tumor-Draining Lymph Nodes
The outcome of crosspresentation is determined by the activa-
tion status of the DCs (Melief, 2003; Steinman et al., 2003). Dur-
ing microbial infection, ‘‘danger signals,’’ including TLR ligands
(Medzhitov, 2007) encoded by the microbe, induce DC matura-
tion, which in turn induces robust IFN-g-producing Th1 cell
responses and cytotoxic T lymphocyte (CTL) responses. In the
case of cancer cells, the extent of DCmaturation that leads to tu-
mor-antigen crosspresentation is usually verymuchweaker than
that induced by virulent microorganisms, despite the fact that
many cancer cells and/or the cancer-associated stroma pos-
sess an inflammatory signature (see above) and despite the
fact that so-called endogenous danger signals (Matzinger,
2002) such as uric acid, heat shock proteins, and high-mobility
group box 1 (HMGB1) protein can cause DC activation from dy-
ing cancer cells (reviewed in van der Most et al., 2008). HMGB1
protein reportedly binds to TLR2 and TLR4 (Park et al., 2006),
consistent with immune activation by dying tumor cells involving
both HMGB1 and TLR4 (Apetoh et al., 2007). A dampening influ-
ence on CD8+ T cell activation by DCs crosspresenting cancer-
associated antigens may be exerted by the selective recruitment
of the pattern recognition receptor pentraxin 3 (PTX3) to the syn-
apse between crosspresenting DCs and dying (apoptotic) cells
(Baruah et al., 2006). PTX3 was found to suppress the CD8+
T cell response to tumor-associated self-antigens, but not to
microbial antigens, indicating an important role of PTX3 in cen-
sorship of autoimmunity (Baruah et al., 2006). Apart from mole-
cules with modulating properties such as pentraxins, another
factor is the amount of apoptosis in growing tumors, which is
apparently too low in many instances to generate enough uric
acid and heat-shock-bound tumor-associated proteins to cause
DC activation. This finding is in line with the immature phenotype
of DCs found in many cancers, and is also consistent with the
fact that optimal crosspresentation of tumor-associated anti-
gens usually needs tumor apoptosis-enhancing treatments.
The result of antigen presentation to either CD4+ or CD8+
T cells by immature or partially mature DC can be deletional
tolerance (Steinman and Nussenzweig, 2002; Steinman et al.,
2003) or induction of regulatory CD4+ T cells (Zou, 2006), regula-
tory CD8+ T cells (Zou, 2006) or of ‘‘poised’’ T cells (van Mierlo
et al., 2002; van Mierlo et al., 2004). The latter population is inter-
esting for therapeutic purposes because these central memory-
like CD8+ T cells that reside in tumor-draining lymph nodes ina mouse model could be rescued for therapy by vigorous DC
stimulation in situ by the injection of TLR ligands (CpG and
LPS) or CD40 agonist monoclonal antibody (van Mierlo et al.,
2002; van Mierlo et al., 2004). Such stimulation was associated
with expansion and systemic spread of CD8+ T cells, presumably
by proper CTL effector programming by DCs in the tumor-drain-
ing lymph nodes that were shown to crosspresent tumor antigen
(van Mierlo et al., 2004). Consistent with that, immature DCs
loaded ex vivo with an MHC class I-binding peptide induced
poised T cells that could be rescued by restimulating the re-
sponse in vivo with infectious virus expressing this CTL epitope
(Dumortier et al., 2005). A potential clinical application of this
finding would be to cause expansion and systemic migration of
T cells from local tumor draining lymph nodes by CD40 agonist
therapy or local TLR ligand administration before surgical re-
moval of tumor-draining lymph nodes. Similar results were
obtained in a different mouse tumor model, in which natural pre-
sentation of a CTL epitope from the melanocyte antigen tyrosi-
nase crosspresented from a transplanted melanoma cell line
caused incomplete CTL activation in tumor-draining lymph no-
des associated with tumor outgrowth (Hargadon et al., 2006).
Once the tumor hadmetastasized to these nodes, direct presen-
tation contributed to this incomplete activation. Ex vivo-acti-
vated DCs loaded with tumor-associated antigen were able to
cause full development of effector CTLs in this situation. A
separate mechanism of activation of resident dormant CTLs
was achieved by intratumoral administration of the TLR ligand
poly (I:C). This resulted in complete tumor resolution caused by
type I IFN-mediated activation of the inert intratumoral CD8+
T cells (Currie et al., 2008). In this case, no systemic migration
of the tumor-specific T cells was observed. Usually, crosspre-
sentation of tumor-associated antigens by DCs is only effective
in the case of high expression and stability of the tumor-associ-
ated protein or in the case of a high spontaneous cancer apopto-
sis or necrosis rate, consistent with the results from model
antigen systems and from DNA-vaccination experiments. If
spontaneous crosspresentation of tumor antigens is insufficient,
processing and presentation can be driven by a variety of tumor
cell-death-promoting therapies, including chemotherapy, cryoa-
blation, hyperthermia, and irradiation (Figure 2).
DC Activation with Cancer Chemotherapeutics
and Other Tumor Cell-Death-Promoting Therapies
Many tumors do not express protein antigens at a sufficiently
high amount to cause ample crosspresentation (Nowak et al.,
2003a; Heath et al., 2004; van der Bruggen and Van den Eynde,
2006; van der Most et al., 2008; Zitvogel et al., 2008). Moreover,
most growing tumors, despite their often inflammatory nature,
do not cause robust DC maturation (Melief, 2003; Zitvogel
et al., 2008). Both of these obstacles can be overcome by certain
forms of cancer chemotherapy. The massive tumor apoptosis
and/or necrosis induced by chemotherapy releases large
amounts of tumor-associated proteins, strongly driving efficient
crosspresentation by tumor-associated DCs in the tumor-drain-
ing lymph nodes (van der Most et al., 2008; Zitvogel et al., 2008)
(Figure 2). In its most extreme form, this even leads to the antigen
loading of not only DCs but also of stroma cells, including vascu-
lar cells, allowing the destruction by CTL-mediated therapy of
even MHC class I-low or -negative tumors (Zhang et al., 2007).Immunity 29, September 19, 2008 ª2008 Elsevier Inc. 375
Immunity
ReviewIn most instances, the enhanced crosspresentation of tumor
antigens by DCs after chemotherapy is not enough to induce a
sufficiently robust T cell response for tumor eradication (van
der Most et al., 2008; Zitvogel et al., 2008). However, after addi-
tional activation of the DCs bymolecularly defined DC-activating
compounds such as CD40 agonistic antibody, a strongly syner-
gistic antitumor effect mediated by tumor-specific CD8+ T cells
has been observed (Nowak et al., 2003a; Nowak et al., 2003b;
Nowak et al., 2006). The benefit of chemotherapy is to allow
the use of the tumor as its own vaccine for appropriate DC load-
ing, thereby necessitating only the use of a strong DC activator to
achieve meaningful therapeutic effects. This has the added ad-
vantage that cancer epitopes based on tumor-unique mutational
sequences will have a chance to induce powerful tumoricidal
T cell responses, without the need to identify and sequence
these mutations. In a study with a murine tumor transduced
with the model antigen influenza hemagglutinin (HA), treatment
Figure 2. Sites of Action of Immunotherapy of Cancer
Different treatment modalities act in concert to thwart the immunosuppression
associated with cancer and promote induction and expansion of effector
T cells by a variety of mechanisms. STAT3 inhibitor reverts immunosuppres-
sion associated with enhanced STAT3 signaling. Low-dose chemotherapy
causes enhanced tumor cell apoptosis, associated with release of uric acid.
This has two effects: enhanced crosspresentation of tumor-associated anti-
gens by DCs and DC activation via crystalline uric acid. Low-dose chemother-
apy also deletes Treg cells, tumor-associated macrophages (TAMs) and
myeloid-derived suppressor cells (MDSCs) and allows homeostatic expansion
of vaccine-driven effector T cells. CD40 agonist antibody and TLR ligands di-
rectly activate DC in tumor-draining lymph nodes, like therapeutic vaccines
driving robust effector T cell responses (Th1 cell and CD8 CTL responses).
CTLA-4 and PD-1 blocking antibodies release the brakes of costimulation
and thereby converts anergic T cells into effector T cells. OX40 agonist anti-
body blocks suppression by regulatory T cells and activates effector T cells.376 Immunity 29, September 19, 2008 ª2008 Elsevier Inc.with the chemotherapeutic drug gemcitabine markedly en-
hanced crosspresentation of HA to CD8+ T cells, without causing
deletion of these T cells. Drug-induced cancer apoptosis primed
the host for a strong antitumor response to vaccination with a
second, influenza virus-mediated HA presentation in a more
costimulatory context (Nowak et al., 2003a).
Certain ‘‘immunogenic’’ forms of cancer chemotherapy that
cause substantial DCactivation bymolecularly definedpathways
even in the absence of added DC-activating compounds have
been described. One of these chemotherapeutic drug classes
are the anthracyclins, DNA-damaging compounds. Anthracy-
clins induce the rapid translocation of calreticulin, an ER-based
molecule in the class I processing pathway, to the cell surface.
This process promoted phagocytosis of cancer cells by DCs
and is associated with DC activation and immunogenicity
in vivo (Obeid et al., 2007). It was subsequently found that the ec-
tocalreticulin display is by itself not sufficient to cause DC activa-
tion and tumor eradication but that the HMGB 1 alarmin protein
secreted by dying tumor cells interacts with TLR4 on DCs to
cause immunogenic crosspresentation (Apetoh et al., 2007).
Another compound, Cyclophosphamide (Cy), can enhance tu-
mor-specific immunity in a variety of ways. Reportedly, a low
dose of Cy selectively depletes CD4+25+ Treg cells (reviewed in
Zou, 2006; van der Most et al., 2008; Zitvogel et al., 2008; and
Brode and Cooke, 2008). Also, Cy and other chemotherapeutic
agents induceproduction of uric acid causedby tumor cell death.
Uric acid, at least supposedly in crystal form, activates DCs, pro-
moting tumor rejection (Hu et al., 2004) (Shi et al., 2003; Shi et al.,
2006c). The considerable DC-activating potency of uric acid was
recently demonstrated by the finding that alum, the most widely
used adjuvant in vaccines, has no intrinsic DC-activating ability
in vivo, but acts through uric-acid-induced DC activation in vivo
(Kool et al., 2008). Cy also induces a profound and systemic
type I IFN release (Schiavoni et al., 2000) that results in DC and
T cell activation and appears to be partially responsible for its
antitumor effect (Mokyr et al., 2006). Finally, many forms of che-
motherapy cause some degree of lymphopenia, which is likely to
create an excellent stage for homeostatic expansion of tumor-
specific CD8+ T cells, in particular in combination with robust
therapeutic vaccination or adoptive transfer of tumor-specific
T cells (Muranski et al., 2006; Rosenberg et al., 2008).
In a murine tumor model system with OVA-transduced B16
melanoma cells, cryoablation with liquid nitrogen of tumors
alone enhanced crosspresentation by DCs in vivo. However,
this process can only lead to highly effective in vivo antigen pre-
sentation by DCswhen performed in combination with additional
DC stimulation by TLR9 ligand CpG vaccine (den Brok et al.,
2006b). In an in vitro study, it was shown that human DCs loaded
with melanoma cells that were heated to 42C and subsequently
killed are more efficient at crosspriming naive human CTL in 3
week cultures than DCs loaded with unheated killed melanoma
cells (Shi et al., 2006a). The heat-treated melanoma cells ex-
pressed enhanced amounts of HSP70, and the enhanced cross-
priming could be reproduced by overexpression of HSP70 in
melanoma cells. The hyperthermia also caused increased tran-
scription of several tumor-associated antigens, including
MAGE-B3, MAGE-B4, MAGE-A8, and MAGE-A10 (Shi et al.,
2006a). Not unexpectedly, tumor cell death caused by radiother-
apy also promotes crosspresentation (Chen et al., 2005; den
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cancer cell death associated with conventional cancer therapies
not only leads to enhanced crosspresentation of tumor-associ-
ated antigens to DCs but also to DC activation by the enhanced
release of uric acid from dead cells. Certain forms of cancer che-
motherapy further enhance DC activation as exemplified by re-
lease of type I IFN after therapy with Cy and ectocalreticulin dis-
play after anthracyclin therapy. Because optimal DC activation
depends on synergistic triggering of several molecules (Napoli-
tani et al., 2005), additional clinical benefit can be achieved by
administration of exogenous TLR ligands and CD40 agonists.
Subsets of DCs that Crosspresent Tumor Antigens
Most data on subsets of DCs involved in crosspresentation to
CTL precursors have been generated in mice (reviewed in Heath
et al., 2004). In this species, the DC subset expressing CD8a is
particularly effective in crosspresentation toCD8CTL precursors
(Heath et al., 2004). The CD8a subset of DC appears to originate
from theCD8anegative subset by amaturation process involving
upregulation of not only CD8abut also theC-type lectin DEC-205
and CD24 (Martinez del Hoyo et al., 2002). The dominant role of
this subset in crosspresentation is not due to differences in
antigen capture but rather to a greater processing efficiency
(Schnorrer et al., 2006). Not all CD8a+ DC appear to possess
this specialized function because intravenous injection of cyto-
chrome C caused apoptosis of approximately half the CD8a+
DC population, but virtually completely ablated crosspresenting
ability and therebyCTL induction, reducing subsequent immunity
to tumor challenge (Lin et al., 2008a). Particularly relevant for
tumor-antigen processing is the finding that CD8+ DCs, residing
in the T-dependent areas in lymph nodes and spleen, are special-
ized in the uptake and crosspresentation of apoptotic cells (Iyoda
et al., 2002; Schulz and Reis e Sousa, 2002). In the crosspresen-
tation of skin-derived antigens, exemplified by herpes simplex
virus skin infection in mice, collaboration was observed between
migratory DCs transporting antigen to sessile lymphoid-resident
DCs (Allan et al., 2006). Similar collaboration between migratory
langerin+CD11b DCs and sessile CD8a DCs was observed in
the clearance of lung infections from acute influenza virus infec-
tion (GeurtsvanKessel et al., 2008). In contrast, plasmacytoid
DCs (pDCs), which are strong type I IFN producers, do not cross-
present toCD4orCD8virus-specific Tcells andare not important
for a protective T cell response to this virus, possibly because in
influenza infection other cell types produce enough type I IFN
(GeurtsvanKessel et al., 2008). Type I IFN is indeed produced
rapidly in response to infection by activated NK cells, pDCs,
and other cell types, but not in cancer, except after cyclophos-
phamide treatment.
Type I IFN, in particular IFN-a, has a major effect on crosspre-
sentation by two distinct mechanisms: promotion of crosspre-
sentation by DC activation (Le Bon et al., 2003) and direct
stimulation of CTL via type I IFN receptors on these T cells
(Le Bon et al., 2006). Mobilizing type I IFN production by pDCs
could therefore have a beneficial effect on crosspresentation
by common CD8a+ DCs and reveal yet another level of collabo-
ration between DC subsets to be exploited for cancer immuno-
therapy. Immature human cDCs, but not mature cDCs, were
found to upregulate STAT1 in response to type I IFN. Conversely,
exposure of mature cDCs to type I IFN leads to signaling viaSTAT4. STAT1 signaling resulted in inhibition of CD40L-induced
IL-12 production, causing inhibition of CD8+ T cell activation
(Longman et al., 2007). Type I IFN signaling therefore has differ-
ential effects on crosspresentation by mature versus immature
cDCs, leading to the conclusion that application of type I IFN in
cancer treatment needs to be conducted with care and should
be applied in conjunction with full DC activation. In a recent
study, TLR9-activated pDCs were directly injected into subcuta-
neous transplanted B16 melanoma tumors in a mouse model.
This treatment induced robust, spontaneous CTL crosspriming
against multiple B16 tumor-associated antigens, causing re-
gression of both the treated tumors as well as of distant contra-
lateral tumors (Liu et al., 2008). The T cell crosspriming was
mediated by cDCs and was completely dependent on the early
recruitment of NK cells at the tumor site (Liu et al., 2008). This
NK cell recruitment was mediated by CCR5 via chemokines se-
creted by the pDCs. The combined data suggest that activated
pDCs can initiate effective and systemic antitumor immunity
through a series of cellular events involving sequential activation
of NK cells, cDCs and CD8+ T cells (Liu et al., 2008).
Human pDCs of melanoma patients can process and present
exogenous proteins to CD4+ T cells after FcgRII-mediated pro-
tein ingestion (Benitez-Ribas et al., 2006). Both Langerhans cells
and cDCs can crosspresent melanoma-associated antigens to
CTL and activate them in vitro (Cao et al., 2007). The conclusion
is that crosspresentation to CTL precursors in tumor systems
involves an intricate interplay between different cell types of
the innate and adaptive immune system.Migratory DCs (from or-
gan-specific tissues) and sessile DCs (in lymphoid organs) are
likely to collaborate in crosspresentation as in the viral systems
discussed above. The prime crosspresenting DC is the cDC,
but orchestration of crosspresentation by cDCs appears to be
mediated by IFN-a-producing pDCs and by NK cells. A very spe-
cial case of crosspresentation of tumor-associated antigens
from apoptotic tumor cells is crosspresentation by liver sinusoi-
dal endothelial cells, which causes CD8+ T cell tolerance (Berg
et al., 2006). This study reveals the existence of yet another pro-
fessional APC subset that in an organ-specific way engages in
crosspresentation of tumor antigens to CD8+ T cells. CD4+ T
helper cells are also likely to play a major role through their
well-established role in CD40L-mediated DC activation (Schoen-
berger et al., 1998; Bennett et al., 1998). Indeed, because of this,
studies of crosspresentation by these DC subsets in tumor
systems should be expanded to MHC class II processing and
presentation. That this can be rewarding is illustrated by a recent
study in mice in which it was shown that a major cause of defec-
tive effector CTL generation against tumors might be defective
MHC class II processing of tumor-associated antigens, rather
than defective crosspresentation to CD8+ T cells (Gerner et al.,
2008).
Therapy with Ex Vivo-Activated DCs versus
Direct In Vivo Targeting of DCs
In the last decade, after the initial successful results with preven-
tive and therapeutic DC vaccination in mice (Mayordomo et al.,
1995), numerous investigators have initiated clinical trials of
established cancer with tumor antigen-loaded DCs, mainly con-
ventional DCs formerly called myeloid DCs as distinct from type I
IFN-producing pDCs. These efforts can help to establish proof ofImmunity 29, September 19, 2008 ª2008 Elsevier Inc. 377
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and dose of antigen and properly activated, as well as properly
migrating to lymph nodes, can initiate and expand tumor-specific
CD4+ and CD8+ T cell responses to inducemeaningful therapeu-
tic responses. So far, despite induction of robust tumor-specific
T cell responses in many patients and occasional spectacular
complete tumor regressions, particularly in patients with mela-
noma, (Steinman and Banchereau, 2007; Palucka et al., 2007;
Lesterhuis et al., 2008), this hope has not been fulfilled. On one
hand, this could be due to many of the problems inherent to
any immunotherapeutic approach of cancer, such as the pres-
ence of various types of suppressive leukocytes with or without
constitutive P-STAT3 signaling (see above), immunoediting
(Dunn et al., 2006; Koebel et al., 2007), abnormal tumor vascula-
ture inhibiting effector T cell entry (Hamzah et al., 2008a; Hamzah
et al., 2008b), or other factors inherent to the tumor cell biology in
its interaction with the stromal environment. On the other hand,
the attempts atDC therapy havebeenplaguedbya lackof knowl-
edge of the ideal antigen-loaded DC for optimal therapy and by
a lack of standardization (Figdor et al., 2004; Steinman and Ban-
chereau, 2007). In many instances, the DCs were loaded with
a limited number of exact HLA-binding peptides with few if any
T helper cell peptides. Such a scheme is suboptimal for induction
of long-lived CTL responses, because these need to be sup-
ported by specific CD4+ T cell responses (Smith et al., 2004;
Melief and van der Burg, 2008). Also, in most instances, such
peptides only bound to one or a limited number of HLA class I
molecules, mainly HLA-A2. Ideally, one would like to properly
load all the available HLA class I- and class II-presenting mole-
cules on the DC with tumor antigen-derived peptides (Melief
and van der Burg, 2008). Several strategies have been tried to
achieve this, such as DC loadingwith tumor-derived RNA (Gilboa
and Vieweg, 2004; Su et al., 2005) or immune complexes (Kaler-
gis and Ravetch, 2002; Rafiq et al., 2002; Schuurhuis et al., 2002;
Schuurhuis et al., 2006b). The latter strategy works well in mouse
models but has not yet been tried in patients. Loading of DCswith
immune complexes consisting of a tumor-associated protein,
complexed to a specific IgG antibody, has the double advantage
of not only efficiently promoting MHC class I and class II presen-
tation to the available MHC molecules on the DC but also
activating the DC through the same Fc receptor(s) (Kalergis and
Ravetch, 2002;Rafiqet al., 2002;Schuurhuis et al., 2002;Schuur-
huis et al., 2006b), apowerfulDCactivationmethod. Fc-receptor-
mediated activation of DC works best via ex vivo loading of the
DC, probably because this allows the use of optimal concentra-
tions of immune complexes in the absence of immune complex
uptake and destruction by macrophages and granulocytes
(Schuurhuis et al., 2006b).
Other DC targeting strategies have proven to operate well both
in vitro and directly in vivo. An attractive DC targeting approach is
the docking ontoC-type lectin receptors onDCsuch asDEC-205
(Steinman et al., 2003; Trumpfheller et al., 2006; Bozzacco et al.,
2007), DC-SIGN (Tacken et al., 2005; Tacken et al., 2008), or
DNGR-1 (Sancho et al., 2008). Tumor antigens equipped with
the sugar moieties docking the antigen to the DC receptors or
tumor antigens, coupled to or incorporated in monoclonal anti-
bodies directed against the C-type lectin receptors (Trumpfheller
et al., 2006; Bozzacco et al., 2007; Sancho et al., 2008), effec-
tively target the antigens into the MHC class I and II processing378 Immunity 29, September 19, 2008 ª2008 Elsevier Inc.pathways of the targeted DC. Because targeting of these recep-
tors is not associated with DC activation, additional DC-activat-
ing compounds such as agonistic antibody directed against
CD40 or TLR ligands need to be given as well (Trumpfheller
et al., 2006). In fact, recent evidence shows that without such
DC-activating compounds, this type of DC targeting can be
used in vivo to induce disease-specific tolerance to beta cells
of pancreatic islets (Mukhopadhaya et al., 2008), reminding us
that a very similar mechanism drives DC-mediated tolerance to
tumor-associated antigens in the absence of proper DC activa-
tion by growing tumors. A similar highly effective targeting of
tumor antigens to DC in vivo can be achieved by injecting pep-
tides coupled to TLR ligands (Khan et al., 2007). The efficiency
of C-type lectin and TLR-ligand-conjugate-mediated antigen
targeting to DCs in vivo raises the question of whether this is
not the way to go, instead of the laborious and expensive
ex vivo loading of DC with tumor antigens.
In many instances, DCs will acquire exogenous antigen in
a very sensitive fashion through specialized receptors. However,
synthetic long peptides are also efficiently acquired by DCs
(Melief and van der Burg, 2008; Bijker et al., 2008), allowing ther-
apeutic vaccination inducing both CD4+ and CD8+ T cell re-
sponses (Zwaveling et al., 2002; Melief and van der Burg,
2008) causing eradication of established high-risk HPV-induced
lesions inmice (Zwaveling et al., 2002) and of established cotton-
tail rabbit-papilloma-virus-induced lesions in rabbits (Vambutas
et al., 2005). In addition, a complete set of overlapping long pep-
tides of the E6 and E7 oncogenic proteins of HPV16 induced
robust immune responses to multiple CD4+ and CD8+ T cell
epitopes of these oncoproteins in patients with cervical cancer
(Kenter et al., 2008; Welters et al., 2008). Such synthetic long
peptides can be easily synthesized under good manufacturing
practice (GMP) conditions, required for clinical use, and in con-
trast to exact MHC class I-binding peptides do not cause
specific immune tolerance (Melief and van der Burg, 2008).
Receptor-mediated targeting can help to further increase the
efficiency of long-peptide DC targeting as shown in mouse
experiments (Khan et al., 2007), but clinical application of this
requires adaptation of conjugate production to GMP conditions.
Advances in Cancer Immunotherapies
A vivid illustration of the overwhelming importance of intact cos-
timulatory pathways in cancer immunity is the vastly improved
resistance against many tumors, including UV-induced skin
carcinogenesis and HPV-induced tumor transplants of mice de-
ficient in the E3 ligase Casitas B cell lymphoma-b (cbl-b) (Loeser
et al., 2007). Cbl-b-deficient T cells are remarkably independent
of costimulation through CD28 on T cells by members of the B7
costimulatory family (such as CD80 and CD86) on antigen-pre-
senting cells, including DCs (Bachmaier et al., 2000; Chiang
et al., 2000; Jeon et al., 2004). The phenotype of the tumor model
could be recapitulated in normal mice by adoptive transfer of
Cbl-b-deficient CD8+ T cells into tumor-bearing wild-type mice
(Loeser et al., 2007). These results indicate that if the balance
of costimulation in tumor-specific CD8+ T cells is reset, the full
power of tumor-reactive T cells can be unleashed and CD8+
T cell-mediated tumor eradication can be achieved. One way to
achieve this in normal mice and patients with cancer is to block
feedback inhibition of costimulation through CD28 by blockade
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treatment with such antibodies, remarkable therapeutic re-
sponses are seen in mice (Sutmuller et al., 2001) and patients
with cancer albeit at the expense of severe autoimmune side
effects (Phan et al., 2003; Sanderson et al., 2005). In a clinical
study of cancer patients treated with CTLA-4-blocking monoclo-
nal antibody, this treatment was observed to expand both effec-
tor CD4+ T cells and Foxp3+ Treg cells (Kavanagh et al., 2008),
consistent with a second study in which the extent of therapy-
induced necrosis in previously vaccinated cancer patients after
subsequent treatment with CTLA-4 blockade was related to
the ratio of effector cells over Treg cells in posttreatment biop-
sies (Hodi et al., 2008). Both clinical studies also suggest that
the combination of CTLA-4 blockade with depletion of Treg cells
has synergistic potential, as indeed observed in a mouse study
(Sutmuller et al., 2001). Detailed insights into expression of acti-
vating and dampening receptors of B7 family costimulatory
molecules and their ligands other than CTLA-4 in cancer and
chronic persistent infections have shown that in these condi-
tions, the expression of inhibitory molecules is upregulated
(Zang and Allison, 2007; Zou and Chen, 2008; Keir et al., 2008).
One pair of B7 family (ligand) molecules with largely inhibitory
functions is represented by PD-1, expressed on activated T cells
and so-called exhausted T cells and a variety of other cell types,
and PD-L1, expressed onmany cell types and overexpressed on
a variety of human cancers (reviewed in Zang and Allison, 2007;
Keir et al., 2008). In chronic persistent virus infection of mice,
T cell responses were enhanced by administration of a monoclo-
nal blocking antibody against PD-L1, associated with a marked
reduction in viral load (Barber et al., 2006). Similar observations
were also made in mouse tumor models. Tumor-associated DCs
were observed to overexpress PD-L1 and PD-1 and PD-L1
blockade by anti-PD-L1-augmented DC-mediated T cell activa-
tion in this model (Curiel et al., 2003). In the B16 mouse mela-
noma model, pDCs from tumor-draining lymph nodes were
found to activatemature Treg cells via production of indoleamine
2,3-dioxigenase (IDO). The suppressive activity of the Treg cells
was blocked by PD-L1 blockade (Sharma et al., 2007). In several
mouse tumor models, promising antitumor effects in vivo have
been observed with PD-1 blockade and a human PD-1 blocking
antibody has been developed and is in phase I clinical studies
(reviewed in Keir et al., 2008). Finally, triggering with agonistic
antibody of the OX40molecule on T cells, such as CD40, amem-
ber of the TNF receptor family, has a highly favorable effect on
tumor-specific T cell immunity, causing local Treg cell depletion
and inactivation and tumor-infiltrating DC maturation and migra-
tion, decreasing TAMs and MDSCs, and lowering of the expres-
sion of TGF-b (Gough et al., 2008; Piconese et al., 2008). This
was associated with enhanced infiltration of tumors with effector
CD8 T cells and increased survival from tumor challenge (Gough
et al., 2008; Piconese et al., 2008) (Figure 2).
Conclusions
Many of the molecular changes that allow a tumor to grow and
infiltrate in its environment also create an immunosuppressive
milieu that counteracts tumor rejection. TAMs and MDSCs con-
spire to counteract the generation of fully activated DCs. Full DC
activation is a problem in tumor immunology because such acti-
vation is more readily accomplished by pathogen-associatedmolecules such as TLR ligands than by cancer-associated trig-
gers of DC activation, underlining the fact that in many ways,
tumors masquerade as self-tissues creating tolerance rather
than immunity. In addition, many tumors overexpress STAT3
protein, in turn causing STAT3 expression in tumor-infiltrating
leukocytes, associated with production of TGF-b and IL-10
and suppression of Th1 cell responses. In this atmosphere rife
with immunosuppressive chemokine and cytokine production,
and inadequately activated DCs, regulatory T cells are gener-
ated. Together, this conflagration of suppressive leukocytes
and improperly activated DCs in many instances is powerless
to generate sufficient numbers of properly activated tumor-spe-
cific Th1 cells and CTLs, despite ample evidence for expression
of tumor-associated antigens in both viral and nonviral cancers.
Nevertheless, in many cases tumor-specific effector T cells co-
exist with the tumor, sometimes even keeping dormant tumors
in check, and therapeutic activity of these cells can be rescued
by robust tumor vaccination in conjunction with therapeutic
measures that tilt the balance in the symbiosis of the tumor
with the immune system toward tumor rejection. These insights
lead to the inescapable conclusion that no single immunothera-
peutic modality can be expected to effectively cure established
cancer. Rather, the remarkable beneficial effects of certain forms
of low-dose chemotherapy, including DC activation, enhanced
crosspresentation of tumor-associated antigens from necrotic
or apoptotic cancer cells, lymphodepletion, and reduction of im-
munosuppressive leukocytes, can be mobilized to act in concert
with therapeutic vaccines or adoptive T cell transfer. Promising
therapeutic vaccines include ex vivo-activated tumor antigen-
loaded DCs, synthetic long peptides targeting DCs and TLR
ligand-peptide conjugates, or chimeric antibodies efficiently
targeting tumor antigens to C-type lectin receptors on DC.
Clearly, the effects of therapeutic cancer vaccines can be
expected to be enhanced further by additional therapies that
redress the immunosuppression associated with cancer. Such
therapies include administration of STAT3 inhibitors, local or
systemic treatment with molecularly defined triggers of DC acti-
vation such as TLR ligands and CD40 agonistic antibody and
treatment with monoclonal antibodies that block deleterious
feedback inhibition pathways, in particular blockers of CTLA-4
and PD-1, or with antibodies that enhance T cell effector func-
tion, including agonists of OX-40.
More than ever, development of effective immunotherapy of
established cancer calls for unprecedented cooperation among
cancer scientists, pharmaceutical companies, and between
scientists and the pharma community. At the same time, science
in this area is now one of the most challenging and exciting in
immunology and medicine.
ACKNOWLEDGMENTS
C.J.M.M. is an employee of the company Immune System Activation (ISA) for
75% of his time and an employee of Leiden University Medical Center for 25%
of his time.
REFERENCES
Albert, M.L., Pearce, S.F., Francisco, L.M., Sauter, B., Roy, P., Silverstein,
R.L., and Bhardwaj, N. (1998). Immature dendritic cells phagocytose apoptotic
cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T
lymphocytes. J. Exp. Med. 188, 1359–1368.Immunity 29, September 19, 2008 ª2008 Elsevier Inc. 379
Immunity
ReviewAllan, R.S., Waithman, J., Bedoui, S., Jones, C.M., Villadangos, J.A., Zhan, Y.,
Lew, A.M., Shortman, K., Heath, W.R., and Carbone, F.R. (2006). Migratory
dendritic cells transfer antigen to a lymph node-resident dendritic cell popula-
tion for efficient CTL priming. Immunity 25, 153–162.
Angeletti, P.C., Zhang, L., and Wood, C. (2008). The viral etiology of AIDS-
associated malignancies. Adv. Pharmacol. 56, 509–557.
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A.,
Mignot, G., Maiuri, M.C., Ullrich, E., Saulnier, P., et al. (2007). Toll-like receptor
4-dependent contribution of the immune system to anticancer chemotherapy
and radiotherapy. Nat. Med. 13, 1050–1059.
Aspord, C., Pedroza-Gonzalez, A., Gallegos, M., Tindle, S., Burton, E.C., Su,
D., Marches, F., Banchereau, J., and Palucka, A.K. (2007). Breast cancer
instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that
facilitate tumor development. J. Exp. Med. 204, 1037–1047.
Atreya, R., and Neurath, M.F. (2008). Signaling molecules: The pathogenic role
of the IL-6/STAT-3 trans signaling pathway in intestinal inflammation and in
colonic cancer. Curr. Drug Targets 9, 369–374.
Bachmaier, K., Krawczyk, C., Kozieradzki, I., Kong, Y.Y., Sasaki, T., Oliveira-
dos-Santos, A., Mariathasan, S., Bouchard, D., Wakeham, A., Itie, A., et al.
(2000). Negative regulation of lymphocyte activation and autoimmunity by
the molecular adaptor Cbl-b. Nature 403, 211–216.
Barber, D.L., Wherry, E.J., Masopust, D., Zhu, B., Allison, J.P., Sharpe, A.H.,
Freeman, G.J., and Ahmed, R. (2006). Restoring function in exhausted CD8
T cells during chronic viral infection. Nature 439, 682–687.
Baruah, P., Propato, A., Dumitriu, I.E., Rovere-Querini, P., Russo, V., Fontana,
R., Accapezzato, D., Peri, G., Mantovani, A., Barnaba, V., and Manfredi, A.A.
(2006). The pattern recognition receptor PTX3 is recruited at the synapse be-
tween dying and dendritic cells, and edits the cross-presentation of self, viral,
and tumor antigens. Blood 107, 151–158.
Becker, Y. (1993). Dendritic cell activity against primary tumors: An overview.
In Vivo 7, 187–191.
Benitez-Ribas, D., Adema, G.J., Winkels, G., Klasen, I.S., Punt, C.J., Figdor,
C.G., and de Vries, I.J. (2006). Plasmacytoid dendritic cells of melanoma
patients present exogenous proteins to CD4+ T cells after Fc gamma RII-
mediated uptake. J. Exp. Med. 203, 1629–1635.
Bennett, S.R., Carbone, F.R., Karamalis, F., Flavell, R.A., Miller, J.F., and
Heath, W.R. (1998). Help for cytotoxic-T-cell responses is mediated by
CD40 signalling. Nature 393, 478–480.
Berg, M., Wingender, G., Djandji, D., Hegenbarth, S., Momburg, F., Hammerl-
ing, G., Limmer, A., and Knolle, P. (2006). Cross-presentation of antigens from
apoptotic tumor cells by liver sinusoidal endothelial cells leads to tumor-spe-
cific CD8+ T cell tolerance. Eur. J. Immunol. 36, 2960–2970.
Bijker, M.S., van den Eeden, S.J., Franken, K.L., Melief, C.J., van der Burg,
S.H., and Offringa, R. (2008). Superior induction of anti-tumor CTL immunity
by extended peptide vaccines involves prolonged, DC-focused antigen
presentation. Eur. J. Immunol. 38, 1033–1042.
Binder, R.J., Kelly, J.B., III, Vatner, R.E., andSrivastava, P.K. (2007). Specific im-
munogenicity of heat shock protein gp96 derives from chaperoned antigenic
peptides and not from contaminating proteins. J. Immunol. 179, 7254–7261.
Bins, A.D., Jorritsma, A., Wolkers, M.C., Hung, C.F., Wu, T.C., Schumacher,
T.N., and Haanen, J.B. (2005). A rapid and potent DNA vaccination strategy
defined by in vivo monitoring of antigen expression. Nat. Med. 11, 899–904.
Bins, A.D., Wolkers, M.C., van den Boom, M.D., Haanen, J.B., and Schu-
macher, T.N. (2007). In vivo antigen stability affects DNA vaccine immunoge-
nicity. J. Immunol. 179, 2126–2133.
Blachere, N.E., Darnell, R.B., and Albert, M.L. (2005). Apoptotic cells deliver
processed antigen to dendritic cells for cross-presentation. PLoSBiol. 3, e185.
Blaskovich, M.A., Sun, J., Cantor, A., Turkson, J., Jove, R., and Sebti, S.M.
(2003). Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal
transducer and activator of transcription 3 signaling pathway inhibitor with
potent antitumor activity against human and murine cancer cells in mice.
Cancer Res. 63, 1270–1279.
Boonman, Z.F., van Mierlo, G.J., Fransen, M.F., de Keizer, R.J., Jager, M.J.,
Melief, C.J., and Toes, R.E. (2005). Maintenance of immune tolerance depends
on normal tissue homeostasis. J. Immunol. 175, 4247–4254.380 Immunity 29, September 19, 2008 ª2008 Elsevier Inc.Borrello, M.G., Degl’innocenti, D., and Pierotti, M.A. (2008). Inflammation and
cancer: The oncogene-driven connection. Cancer Lett. 267, 262–270.
Bozzacco, L., Trumpfheller, C., Siegal, F.P., Mehandru, S., Markowitz, M., Car-
rington, M., Nussenzweig, M.C., Piperno, A.G., and Steinman, R.M. (2007).
DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein
to CD8+ T cells in a spectrum of human MHC I haplotypes. Proc. Natl. Acad.
Sci. USA 104, 1289–1294.
Brode, S., and Cooke, A. (2008). Immune-potentiating effects of the chemo-
therapeutic drug cyclophosphamide. Crit. Rev. Immunol. 28, 109–126.
Cao, T., Ueno, H., Glaser, C., Fay, J.W., Palucka, A.K., and Banchereau, J.
(2007). Both Langerhans cells and interstitial DC cross-present melanoma
antigens and efficiently activate antigen-specific CTL. Eur. J. Immunol. 37,
2657–2667.
Chen, Z., Xia, D., Bi, X., Saxena, A., Sidhu, N., El-Gayed, A., and Xiang, J.
(2005). Combined radiation therapy and dendritic cell vaccine for treating solid
tumors with liver micro-metastasis. J. Gene Med. 7, 506–517.
Chiang, Y.J., Kole, H.K., Brown, K., Naramura, M., Fukuhara, S., Hu, R.J.,
Jang, I.K., Gutkind, J.S., Shevach, E., and Gu, H. (2000). Cbl-b regulates the
CD28 dependence of T-cell activation. Nature 403, 216–220.
Curiel, T.J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R.,
Knutson, K.L., Daniel, B., Zimmermann, M.C., et al. (2003). Blockade of B7–H1
improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 9,
562–567.
Currie, A.J., van der Most, R.G., Broomfield, S.A., Prosser, A.C., Tovey, M.G.,
and Robinson, B.W. (2008). Targeting the effector site with IFN-alphabeta-in-
ducing TLR ligands reactivates tumor-resident CD8 T cell responses to erad-
icate established solid tumors. J. Immunol. 180, 1535–1544.
Da Silva, D.M., Fausch, S.C., Verbeek, J.S., and Kast, W.M. (2007). Uptake of
human papillomavirus virus-like particles by dendritic cells is mediated by
Fcgamma receptors and contributes to acquisition of T cell immunity. J. Immu-
nol. 178, 7587–7597.
Daud, A.I., Mirza, N., Lenox, B., Andrews, S., Urbas, P., Gao, G.X., Lee, J.H.,
Sondak, V.K., Riker, A.I., Deconti, R.C., and Gabrilovich, D. (2008). Phenotypic
and functional analysis of dendritic cells and clinical outcome in patients with
high-risk melanoma treated with adjuvant granulocyte macrophage colony-
stimulating factor. J. Clin. Oncol. 26, 3235–3241.
de Jong, A., van Poelgeest, M.I., van der Hulst, J.M., Drijfhout, J.W., Fleuren,
G.J., Melief, C.J., Kenter, G., Offringa, R., and van der Burg, S.H. (2004).
Human papillomavirus type 16-positive cervical cancer is associated with
impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer
Res. 64, 5449–5455.
den Brok, M.H., Sutmuller, R.P., Nierkens, S., Bennink, E.J., Frielink, C., Too-
nen, L.W., Boerman, O.C., Figdor, C.G., Ruers, T.J., and Adema, G.J. (2006a).
Efficient loading of dendritic cells following cryo and radiofrequency ablation in
combination with immune modulation induces anti-tumour immunity. Br. J.
Cancer 95, 896–905.
den Brok, M.H., Sutmuller, R.P., Nierkens, S., Bennink, E.J., Toonen, L.W.,
Figdor, C.G., Ruers, T.J., and Adema, G.J. (2006b). Synergy between in situ
cryoablation and TLR9 stimulation results in a highly effective in vivo dendritic
cell vaccine. Cancer Res. 66, 7285–7292.
Dhodapkar, M.V., Dhodapkar, K.M., and Palucka, A.K. (2008). Interactions of
tumor cells with dendritic cells: Balancing immunity and tolerance. Cell Death
Differ. 15, 39–50.
Dolan, B.P., Gibbs, K.D., Jr., and Ostrand-Rosenberg, S. (2006). Dendritic
cells cross-dressed with peptide MHC class I complexes prime CD8+
T cells. J. Immunol. 177, 6018–6024.
Dumortier, H., van Mierlo, G.J., Egan, D., van Ewijk, W., Toes, R.E., Offringa,
R., and Melief, C.J. (2005). Antigen presentation by an immature myeloid den-
dritic cell line does not cause CTL deletion in vivo, but generates CD8+ central
memory-like T cells that can be rescued for full effector function. J. Immunol.
175, 855–863.
Dunn, G.P., Koebel, C.M., and Schreiber, R.D. (2006). Interferons, immunity
and cancer immunoediting. Nat. Rev. Immunol. 6, 836–848.
Figdor, C.G., de Vries, I.J., Lesterhuis, W.J., and Melief, C.J. (2004). Dendritic
cell immunotherapy: Mapping the way. Nat. Med. 10, 475–480.
Immunity
ReviewFinn, O.J. (2008). Cancer immunology. N. Engl. J. Med. 358, 2704–2715.
Fonseca, C., and Dranoff, G. (2008). Capitalizing on the immunogenicity of
dying tumor cells. Clin. Cancer Res. 14, 1603–1608.
Gabrilovich, D. (2004). Mechanisms and functional significance of tumour-
induced dendritic-cell defects. Nat. Rev. Immunol. 4, 941–952.
Gerner, M.Y., Casey, K.A., and Mescher, M.F. (2008). Defective MHC class II
presentation by dendritic cells limits CD4 T cell help for antitumor CD8 T cell
responses. J. Immunol. 181, 155–164.
GeurtsvanKessel, C.H., Willart, M.A., van Rijt, L.S., Muskens, F., Kool, M.,
Baas, C., Thielemans, K., Bennett, C., Clausen, B.E., Hoogsteden, H.C., Oster-
haus, A.D., Rimmelzwaan, G.F., and Lambrecht, B.N. (2008). Clearance of
influenza virus from the lung depends on migratory langerin+CD11b- but not
plasmacytoid dendritic cells. J. Exp. Med. 205, 1621–1634.
Ghiringhelli, F., Puig, P.E., Roux, S., Parcellier, A., Schmitt, E., Solary, E.,
Kroemer, G., Martin, F., Chauffert, B., and Zitvogel, L. (2005). Tumor cells con-
vert immature myeloid dendritic cells into TGF-beta-secreting cells inducing
CD4+CD25+ regulatory T cell proliferation. J. Exp. Med. 202, 919–929.
Gilboa, E., and Vieweg, J. (2004). Cancer immunotherapy with mRNA-trans-
fected dendritic cells. Immunol. Rev. 199, 251–263.
Giodini, A., and Cresswell, P. (2008). Hsp90-mediated cytosolic refolding of
exogenous proteins internalized by dendritic cells. EMBO J. 27, 201–211.
Gough, M.J., Ruby, C.E., Redmond, W.L., Dhungel, B., Brown, A., and Wein-
berg, A.D. (2008). OX40 agonist therapy enhances CD8 infiltration and
decreases immune suppression in the tumor. Cancer Res. 68, 5206–5215.
Grulich, A.E., van Leeuwen, M.T., Falster, M.O., and Vajdic, C.M. (2007). Inci-
dence of cancers in people with HIV/AIDS compared with immunosuppressed
transplant recipients: A meta-analysis. Lancet 370, 59–67.
Hamzah,J., Jugold,M.,Kiessling,F.,Rigby,P.,Manzur,M.,Marti,H.H.,Rabie,T.,
Kaden,S.,Grone,H.J.,Hammerling,G.J., et al. (2008a).Vascularnormalization in
Rgs5-deficient tumours promotes immune destruction. Nature 453, 410–414.
Hamzah, J., Nelson, D., Moldenhauer, G., Arnold, B., Hammerling, G.J., and
Ganss, R. (2008b). Vascular targeting of anti-CD40 antibodies and IL-2 into
autochthonous tumors enhances immunotherapy in mice. J. Clin. Invest.
118, 1691–1699.
Hargadon, K,M,, Brinkman, C.C., Sheasley-O’neill, S.L., Nichols, L.A., Bullock,
T.N., and Engelhard, V.H. (2006). Incomplete differentiation of antigen-specific
CD8 T cells in tumor-draining lymph nodes. J. Immunol. 177, 6081–6090.
Harshyne, L.A., Watkins, S.C., Gambotto, A., and Barratt-Boyes, S.M. (2001).
Dendritic cells acquire antigens from live cells for cross-presentation to CTL. J.
Immunol. 166, 3717–3723.
Hasan, U.A., Bates, E., Takeshita, F., Biliato, A., Accardi, R., Bouvard, V., Man-
sour, M., Vincent, I., Gissmann, L., Iftner, T., et al. (2007). TLR9 expression and
function is abolished by the cervical cancer-associated human papillomavirus
type 16. J. Immunol. 178, 3186–3197.
Heath, W.R., Belz, G.T., Behrens, G.M., Smith, C.M., Forehan, S.P., Parish,
I.A., Davey, G.M., Wilson, N.S., Carbone, F.R., and Villadangos, J.A. (2004).
Cross-presentation, dendritic cell subsets, and the generation of immunity
to cellular antigens. Immunol. Rev. 199, 9–26.
Hodi, F.S., Butler, M., Oble, D.A., Seiden, M.V., Haluska, F.G., Kruse, A.,
Macrae, S., Nelson, M., Canning, C., Lowy, I., et al. (2008). Immunologic and
clinical effects of antibody blockade of cytotoxic T lymphocyte-associated
antigen 4 in previously vaccinated cancer patients. Proc. Natl. Acad. Sci.
USA 105, 3005–3010.
Hu, D.E., Moore, A.M., Thomsen, L.L., and Brindle, K.M. (2004). Uric acid
promotes tumor immune rejection. Cancer Res. 64, 5059–5062.
Iyoda, T., Shimoyama, S., Liu, K., Omatsu, Y., Akiyama, Y., Maeda, Y., Taka-
hara, K., Steinman, R.M., and Inaba, K. (2002). The CD8+ dendritic cell subset
selectively endocytoses dying cells in culture and in vivo. J. Exp. Med. 195,
1289–1302.
Jeon, M.S., Atfield, A., Venuprasad, K., Krawczyk, C., Sarao, R., Elly, C., Yang,
C., Arya, S., Bachmaier, K., Su, L., et al. (2004). Essential role of the E3 ubiquitin
ligase Cbl-b in T cell anergy induction. Immunity 21, 167–177.Kalergis, A.M., and Ravetch, J.V. (2002). Inducing tumor immunity through the
selective engagement of activating Fcgamma receptors on dendritic cells. J.
Exp. Med. 195, 1653–1659.
Kavanagh, B., O’Brien, S., Lee, D., Hou, Y., Weinberg, V., Rini, B., Allison, J.P.,
Small, E.J., and Fong, L. (2008). CTLA4 blockade expands FoxP3+ regulatory
and activated effector CD4+ T cells in a dose-dependant fashion. Blood 112,
1175–1183.
Keir, M.E., Butte, M.J., Freeman, G.J., and Sharpe, A.H. (2008). PD-1 and its
ligands in tolerance and immunity. Annu. Rev. Immunol. 26, 677–704.
Kenter, G.G., Welters, M.J., Valentijn, A.R., Lowik, M.J., Berends-van der
Meer, D.M., Vloon, A.P., Drijfhout, J.W., Wafelman, A.R., Oostendorp, J., Fleu-
ren, G.J., et al. (2008). Phase I immunotherapeutic trial with long peptides
spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in
end-stage cervical cancer patients shows low toxicity and robust immunoge-
nicity. Clin. Cancer Res. 14, 169–177.
Khan, S., Bijker, M.S., Weterings, J.J., Tanke, H.J., Adema, G.J., van Hall, T.,
Drijfhout, J.W., Melief, C.J., Overkleeft, H.S., van der Marel, G.A., et al. (2007).
Distinct uptake mechanisms but similar intracellular processing of two differ-
ent toll-like receptor ligand-peptide conjugates in dendritic cells. J. Biol.
Chem. 282, 21145–21159.
Koebel, C.M., Vermi, W., Swann, J.B., Zerafa, N., Rodig, S.J., Old, L.J., Smyth,
M.J., and Schreiber, R.D. (2007). Adaptive immunity maintains occult cancer in
an equilibrium state. Nature 450, 903–907.
Konda, A., and Duffy, M.C. (2008). Surveillance of patients at increased risk of
colon cancer: Inflammatory bowel disease and other conditions. Gastroen-
terol. Clin. North Am. 37, 191–213.
Kool, M., Soullie´, T., van Nimwegen, M., Willart, M.A., Muskens, F., Jung, S.,
Hoogsteden, H.C., Hammad, H., and Lambrecht, B.N. (2008). Alum adjuvant
boosts adaptive immunity by inducing uric acid and activating inflammatory
dendritic cells. J. Exp. Med. 205, 869–882.
Kortylewski, M., Kujawski, M., Wang, T., Wei, S., Zhang, S., Pilon-Thomas, S.,
Niu, G., Kay, H., Mule, J., Kerr, W.G., et al. (2005). Inhibiting Stat3 signaling in
the hematopoietic system elicits multicomponent antitumor immunity. Nat.
Med. 11, 1314–1321.
Kortylewski, M., and Yu, H. (2008). Role of Stat3 in suppressing anti-tumor
immunity. Curr. Opin. Immunol. 20, 228–233.
Kurts, C., Sutherland, R.M., Davey, G., Li, M., Lew, A.M., Blanas, E., Carbone,
F.R., Miller, J.F., and Heath, W.R. (1999). CD8 T cell ignorance or tolerance to
islet antigens depends on antigen dose. Proc. Natl. Acad. Sci. USA 96,
12703–12707.
Le Bon, A., Durand, V., Kamphuis, E., Thompson, C., Bulfone-Paus, S., Ross-
mann, C., Kalinke, U., and Tough, D.F. (2006). Direct stimulation of T cells by
type I IFN enhances the CD8+ T cell response during cross-priming. J. Immu-
nol. 176, 4682–4689.
Le Bon, A., Etchart, N., Rossmann, C., Ashton, M., Hou, S., Gewert, D.,
Borrow, P., and Tough, D.F. (2003). Cross-priming of CD8+ T cells stimulated
by virus-induced type I interferon. Nat. Immunol. 4, 1009–1015.
Lenz, P., Day, P.M., Pang, Y.Y., Frye, S.A., Jensen, P.N., Lowy, D.R., and
Schiller, J.T. (2001). Papillomavirus-like particles induce acute activation of
dendritic cells. J. Immunol. 166, 5346–5355.
Lesterhuis, W.J., Aarntzen, E.H., De Vries, I.J., Schuurhuis, D.H., Figdor, C.G.,
Adema, G.J., and Punt, C.J. (2008). Dendritic cell vaccines in melanoma: From
promise to proof? Crit. Rev. Oncol. Hematol. 66, 118–134.
Lin, M.L., Zhan, Y., Proietto, A.I., Prato, S., Wu, L., Heath, W.R., Villadangos,
J.A., and Lew, A.M. (2008a). Selective suicide of cross-presenting CD8+ den-
dritic cells by cytochrome c injection shows functional heterogeneity within
this subset. Proc. Natl. Acad. Sci. USA 105, 3029–3034.
Lin,M.L., Zhan, Y., Villadangos, J.A., and Lew, A.M. (2008b). The cell biology of
cross-presentation and the role of dendritic cell subsets. Immunol. Cell Biol.
86, 353–362.
Liu, C., Lou, Y., Lizee, G., Qin, H., Liu, S., Rabinovich, B., Kim, G.J., Wang,
Y.H., Ye, Y., Sikora, A.G., et al. (2008). Plasmacytoid dendritic cells induce
NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor re-
gression in mice. J. Clin. Invest. 118, 1165–1175.Immunity 29, September 19, 2008 ª2008 Elsevier Inc. 381
Immunity
ReviewLoeser, S., Loser, K., Bijker, M.S., Rangachari, M., van der Burg, S.H., Wada,
T., Beissert, S., Melief, C.J., and Penninger, J.M. (2007). Spontaneous tumor
rejection by cbl-b-deficient CD8+ T cells. J. Exp. Med. 204, 879–891.
Longman, R.S., Braun, D., Pellegrini, S., Rice, C.M., Darnell, R.B., and Albert,
M.L. (2007). Dendritic-cell maturation alters intracellular signaling networks,
enabling differential effects of IFN-alpha/beta on antigen cross-presentation.
Blood 109, 1113–1122.
Luckashenak, N., Schroeder, S., Endt, K., Schmidt, D., Mahnke, K., Bach-
mann, M.F., Marconi, P., Deeg, C.A., and Brocker, T. (2008). Constitutive
crosspresentation of tissue antigens by dendritic cells controls CD8+ T cell
tolerance in vivo. Immunity 28, 521–532.
Mantovani, A., and Pierotti, M.A. (2008). Cancer and inflammation: A complex
relationship. Cancer Lett. 267, 180–181.
Marigo, I., Dolcetti, L., Serafini, P., Zanovello, P., and Bronte, V. (2008). Tumor-
induced tolerance and immune suppression by myeloid derived suppressor
cells. Immunol. Rev. 222, 162–179.
Martinez del Hoyo, G., Martı´n, P., Arias, C.F., Marı´n, A.R., and Ardavı´n, C.
(2002). CD8alpha+ dendritic cells originate from the CD8alpha- dendritic cell
subset by a maturation process involving CD8alpha, DEC-205, and CD24
up-regulation. Blood 99, 999–1004.
Matzinger, P. (2002). The danger model: A renewed sense of self. Science 296,
301–305.
Mayordomo, J.I., Zorina, T., Storkus, W.J., Zitvogel, L., Celluzzi, C., Falo, L.D.,
Melief, C.J., Ildstad, S.T., Kast, W.M., and Deleo, A.B. (1995). Bone marrow-
derived dendritic cells pulsed with synthetic tumour peptides elicit protective
and therapeutic antitumour immunity. Nat. Med. 1, 1297–1302.
Medzhitov, R. (2007). Recognition of microorganisms and activation of the
immune response. Nature 449, 819–826.
Melief, C.J. (2003). Mini-review: Regulation of cytotoxic T lymphocyte
responses by dendritic cells: Peaceful coexistence of cross-priming and direct
priming? Eur. J. Immunol. 33, 2645–2654.
Melief, C.J., and van der Burg, S.H. (2008). Immunotherapy of established
(pre)malignant disease by synthetic long peptide vaccines. Nat. Rev. Cancer
8, 351–360.
Mokyr, M.B., Place, A.T., Artwohl, J.E., and Valli, V.E. (2006). Importance of
signaling via the IFN-alpha/beta receptor on host cells for the realization of
the therapeutic benefits of cyclophosphamide for mice bearing a large
MOPC-315 tumor. Cancer Immunol. Immunother. 55, 459–468.
Mukhopadhaya, A., Hanafusa, T., Jarchum, I., Chen, Y.G., Iwai, Y., Serreze,
D.V., Steinman, R.M., Tarbell, K.V., and DiLorenzo, T.P. (2008). Selective
delivery of beta cell antigen to dendritic cells in vivo leads to deletion and
tolerance of autoreactive CD8+ T cells in NOD mice. Proc. Natl. Acad. Sci.
USA 105, 6374–6379.
Muranski, P., Boni, A., Wrzesinski, C., Citrin, D.E., Rosenberg, S.A., Childs, R.,
and Restifo, N.P. (2006). Increased intensity lymphodepletion and adoptive
immunotherapy–how far can we go? Nat. Clin. Pract. Oncol. 3, 668–681.
Nagaraj, S., and Gabrilovich, D.I. (2008). Tumor escape mechanism governed
by myeloid-derived suppressor cells. Cancer Res. 68, 2561–2563.
Napolitani, G., Rinaldi, A., Bertoni, F., Sallusto, F., and Lanzavecchia, A. (2005).
Selected Toll-like receptor agonist combinations synergistically trigger a T
helper type 1-polarizing program in dendritic cells. Nat. Immunol. 6, 769–776.
Nees, M., Geoghegan, J.M., Hyman, T., Frank, S., Miller, L., and Woodworth,
C.D. (2001). Papillomavirus type 16 oncogenes downregulate expression of
interferon-responsive genes and upregulate proliferation-associated and
NF-kappaB-responsive genes in cervical keratinocytes. J. Virol. 75, 4283–
4296.
Neijssen, J., Herberts, C., Drijfhout, J.W., Reits, E., Janssen, L., and Neefjes, J.
(2005). Cross-presentation by intercellular peptide transfer through gap junc-
tions. Nature 434, 83–88.
Nguyen, L.T., Elford, A.R., Murakami, K., Garza, K.M., Schoenberger, S.P.,
Odermatt, B., Speiser, D.E., and Ohashi, P.S. (2002). Tumor growth enhances
cross-presentation leading to limited T cell activation without tolerance. J. Exp.
Med. 195, 423–435.382 Immunity 29, September 19, 2008 ª2008 Elsevier Inc.Norbury, C.C., Basta, S., Donohue, K.B., Tscharke, D.C., Princiotta, M.F.,
Berglund, P., Gibbs, J., Bennink, J.R., and Yewdell, J.W. (2004). CD8+ T cell
cross-priming via transfer of proteasome substrates. Science 304, 1318–1321.
Nowak, A.K., Lake, R.A., Marzo, A.L., Scott, B., Heath, W.R., Collins, E.J., Fre-
linger, J.A., and Robinson, B.W. (2003a). Induction of tumor cell apoptosis
in vivo increases tumor antigen cross-presentation, cross-priming rather than
cross-tolerizing host tumor-specific CD8 T cells. J. Immunol. 170, 4905–4913.
Nowak, A.K., Lake, R.A., and Robinson, B.W. (2006). Combined chemoimmu-
notherapy of solid tumours: Improving vaccines? Adv. Drug Deliv. Rev. 58,
975–990.
Nowak, A.K., Robinson, B.W., and Lake, R.A. (2003b). Synergy between
chemotherapy and immunotherapy in the treatment of established murine
solid tumors. Cancer Res. 63, 4490–4496.
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G.M., Apetoh, L., Perfettini, J.L.,
Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007). Calreticulin
exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13,
54–61.
Palucka, A.K., Ueno, H., Fay, J.W., and Banchereau, J. (2007). Taming cancer
by inducing immunity via dendritic cells. Immunol. Rev. 220, 129–150.
Park, J.S., Gamboni-Robertson, F., He, Q., Svetkauskaite, D., Kim, J.Y., Stras-
sheim, D., Sohn, J.W., Yamada, S., Maruyama, I., Banerjee, A., et al. (2006).
High mobility group box 1 protein interacts with multiple Toll-like receptors.
Am. J. Physiol. Cell Physiol. 290, C917–C924.
Phan, G.Q., Yang, J.C., Sherry, R.M., Hwu, P., Topalian, S.L., Schwartzen-
truber, D.J., Restifo, N.P., Haworth, L.R., Seipp, C.A., Freezer, L.J., et al.
(2003). Cancer regression and autoimmunity induced by cytotoxic T lympho-
cyte-associated antigen 4 blockade in patients with metastatic melanoma.
Proc. Natl. Acad. Sci. USA 100, 8372–8377.
Piconese, S., Valzasina, B., and Colombo, M.P. (2008). OX40 triggering blocks
suppression by regulatory T cells and facilitates tumor rejection. J. Exp. Med.
205, 825–839.
Rafiq, K., Bergtold, A., and Clynes, R. (2002). Immune complex-mediated
antigen presentation induces tumor immunity. J. Clin. Invest. 110, 71–79.
Rosenberg, S.A., Restifo, N.P., Yang, J.C., Morgan, R.A., and Dudley, M.E.
(2008). Adoptive cell transfer: A clinical path to effective cancer immunother-
apy. Nat. Rev. Cancer 8, 299–308.
Sancho, D., Moura˜o-Sa´, D., Joffre, O.P., Schulz, O., Rogers, N.C., Pennington,
D.J.,Carlyle,J.R.,andReis eSousa,C. (2008).Tumor therapy inmiceviaantigen
targeting to a novel, DC-restrictedC-type lectin. J. Clin. Invest.118, 2098–2110.
Sandel, M.H., Dadabayev, A.R., Menon, A.G., Morreau, H., Melief, C.J., Off-
ringa, R., van der Burg, S.H., Janssen-van Rhijn, C.M., Ensink, N.G., Tollenaar,
R.A., et al. (2005). Prognostic value of tumor-infiltrating dendritic cells in colo-
rectal cancer: Role of maturation status and intratumoral localization. Clin.
Cancer Res. 11, 2576–2582.
Sanderson, K., Scotland, R., Lee, P., Liu, D., Groshen, S., Snively, J., Sian, S.,
Nichol, G., Davis, T., Keler, T., et al. (2005). Autoimmunity in a phase I trial of
a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody
with multiple melanoma peptides and Montanide ISA 51 for patients with re-
sected stages III and IV melanoma. J. Clin. Oncol. 23, 741–750.
Schiavoni, G., Mattei, F., Di, P.T., Santini, S.M., Bracci, L., Belardelli, F., and
Proietti, E. (2000). Cyclophosphamide induces type I interferon and augments
the number of CD44(hi) T lymphocytes in mice: Implications for strategies of
chemoimmunotherapy of cancer. Blood 95, 2024–2030.
Schnorrer, P., Behrens, G.M., Wilson, N.S., Pooley, J.L., Smith, C.M., El-Suk-
kari, D., Davey, G., Kupresanin, F., Li, M., Maraskovsky, E., et al. (2006). The
dominant role of CD8+ dendritic cells in cross-presentation is not dictated
by antigen capture. Proc. Natl. Acad. Sci. USA 103, 10729–10734.
Schoenberger, S.P., Toes, R.E., van der Voort, E.I., Offringa, R., and Melief,
C.J. (1998). T-cell help for cytotoxic T lymphocytes is mediated by CD40–
CD40L interactions. Nature 393, 480–483.
Schulz, O., and Reis e Sousa, C. (2002). Cross-presentation of cell-associated
antigens by CD8alpha+ dendritic cells is attributable to their ability to internal-
ize dead cells. Immunology 107, 183–189.
Schuurhuis, D.H., Fu, N., Ossendorp, F., and Melief, C.J. (2006a). Ins and outs
of dendritic cells. Int. Arch. Allergy Immunol. 140, 53–72.
Immunity
ReviewSchuurhuis, D.H., Ioan-Facsinay, A., Nagelkerken, B., van Schip, J.J., Sedlik,
C., Melief, C.J., Verbeek, J.S., and Ossendorp, F. (2002). Antigen-antibody
immune complexes empower dendritic cells to efficiently prime specific
CD8+ CTL responses in vivo. J. Immunol. 168, 2240–2246.
Schuurhuis, D.H., van Montfoort, N., Ioan-Facsinay, A., Jiawan, R., Camps,
M., Nouta, J., Melief, C.J., Verbeek, J.S., and Ossendorp, F. (2006b). Immune
complex-loaded dendritic cells are superior to soluble immune complexes as
antitumor vaccine. J. Immunol. 176, 4573–4580.
Sharma, M.D., Baban, B., Chandler, P., Hou, D.Y., Singh, N., Yagita, H.,
Azuma, M., Blazar, B.R., Mellor, A.L., and Munn, D.H. (2007). Plasmacytoid
dendritic cells from mouse tumor-draining lymph nodes directly activate
mature Tregs via indoleamine 2,3-dioxygenase. J. Clin. Invest. 117,
2570–2582.
Shi, H., Cao, T., Connolly, J.E., Monnet, L., Bennett, L., Chapel, S., Bagnis, C.,
Mannoni, P., Davoust, J., Palucka, A.K., and Banchereau, J. (2006a). Hyper-
thermia enhances CTL cross-priming. J. Immunol. 176, 2134–2141.
Shi, X., Franko, B., Frantz, C., Amin, H.M., and Lai, R. (2006b). JSI-124 (cucur-
bitacin I) inhibits Janus kinase-3/signal transducer and activator of transcrip-
tion-3 signalling, downregulates nucleophosmin-anaplastic lymphoma kinase
(ALK), and induces apoptosis in ALK-positive anaplastic large cell lymphoma
cells. Br. J. Haematol. 135, 26–32.
Shi, Y., Evans, J.E., and Rock, K.L. (2003). Molecular identification of a danger
signal that alerts the immune system to dying cells. Nature 425, 516–521.
Shi, Y., Galusha, S.A., and Rock, K.L. (2006c). Cutting edge: Elimination of an
endogenous adjuvant reduces the activation of CD8 T lymphocytes to trans-
planted cells and in an autoimmune diabetes model. J. Immunol. 176, 3905–
3908.
Sica, A., and Bronte, V. (2007). Altered macrophage differentiation and
immune dysfunction in tumor development. J. Clin. Invest. 117, 1155–1166.
Smith, C.M., Wilson, N.S., Waithman, J., Villadangos, J.A., Carbone, F.R.,
Heath, W.R., and Belz, G.T. (2004). Cognate CD4(+) T cell licensing of dendritic
cells in CD8(+) T cell immunity. Nat. Immunol. 5, 1143–1148.
Soria, G., and Ben-Baruch, A. (2008). The inflammatory chemokines CCL2 and
CCL5 in breast cancer. Cancer Lett. 267, 271–285.
Steinman, R.M., and Banchereau, J. (2007). Taking dendritic cells into medi-
cine. Nature 449, 419–426.
Steinman, R.M., Hawiger, D., and Nussenzweig, M.C. (2003). Tolerogenic
dendritic cells. Annu. Rev. Immunol. 21, 685–711.
Steinman, R.M., and Nussenzweig, M.C. (2002). Avoiding horror autotoxicus:
The importance of dendritic cells in peripheral T cell tolerance. Proc. Natl.
Acad. Sci. USA 99, 351–358.
Su, Z., Dannull, J., Yang, B.K., Dahm, P., Coleman, D., Yancey, D., Sichi, S.,
Niedzwiecki, D., Boczkowski, D., Gilboa, E., and Vieweg, J. (2005). Telome-
rase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and
CD4+ T cell responses in patients withmetastatic prostate cancer. J. Immunol.
174, 3798–3807.
Sutmuller, R.P., van Duivenvoorde, L.M., van Elsas, A., Schumacher, T.N.,
Wildenberg, M.E., Allison, J.P., Toes, R.E., Offringa, R., and Melief, C.J.
(2001). Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade
and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alter-
native pathways for suppression of autoreactive cytotoxic T lymphocyte
responses. J. Exp. Med. 194, 823–832.
Tacken, P.J., de Vries, I.J., Gijzen, K., Joosten, B., Wu, D., Rother, R.P., Faas,
S.J., Punt, C.J., Torensma, R., Adema, G.J., and Figdor, C.G. (2005). Effective
induction of naive and recall T-cell responses by targeting antigen to human
dendritic cells via a humanized anti-DC-SIGNantibody. Blood 106, 1278–1285.
Tacken, P.J., Joosten, B., Reddy, A., Wu, D., Eek, A., Laverman, P., Kretz-
Rommel, A., Adema, G.J., Torensma, R., and Figdor, C.G. (2008). No advan-
tage of cell-penetrating peptides over receptor-specific antibodies in targeting
antigen to human dendritic cells for cross-presentation. J. Immunol. 180,
7687–7696.
Trumpfheller, C., Finke, J.S., Lopez, C.B., Moran, T.M., Moltedo, B.,
Soares, H., Huang, Y., Schlesinger, S.J., Park, C.G., Nussenzweig, M.C.,
et al. (2006). Intensified and protective CD4+ T cell immunity in mice with
anti-dendritic cell HIV gag fusion antibody vaccine. J. Exp. Med. 203,
607–617.Vainer, G.W., Pikarsky, E., and Ben-Neriah, Y. (2008). Contradictory functions
of NF-kappaB in liver physiology and cancer. Cancer Lett. 267, 182–188.
Vambutas, A., DeVoti, J., Nouri, M., Drijfhout, J.W., Lipford, G.B., Bonagura,
V.R., van der Burg, S.H., and Melief, C.J. (2005). Therapeutic vaccination
with papillomavirus E6 and E7 long peptides results in the control of both
established virus-induced lesions and latently infected sites in a pre-clinical
cottontail rabbit papillomavirus model. Vaccine 23, 5271–5280.
van der Bruggen, P., and Van den Eynde, B.J. (2006). Processing and presen-
tation of tumor antigens and vaccination strategies. Curr. Opin. Immunol. 18,
98–104.
van der Most, R.G., Currie, A.J., Robinson, B.W., and Lake, R.A. (2008). De-
coding dangerous death: How cytotoxic chemotherapy invokes inflammation,
immunity or nothing at all. Cell Death Differ. 15, 13–20.
van Kester, M.S., Out-Luiting, J.J., von demBorne, P.A., Willemze, R., Tensen,
C.P., and Vermeer, M.H. (2008). Cucurbitacin I inhibits Stat3 and induces
apoptosis in Sezary cells. J. Invest. Dermatol. 128, 1691–1695.
van Mierlo, G.J., Boonman, Z.F., Dumortier, H.M., den Boer, A.T., Fransen,
M.F., Nouta, J., van der Voort, E.I., Offringa, R., Toes, R.E., and Melief, C.J.
(2004). Activation of dendritic cells that cross-present tumor-derived
antigen licenses CD8+ CTL to cause tumor eradication. J. Immunol. 173,
6753–6759.
vanMierlo,G.J., denBoer, A.T.,Medema,J.P., vanderVoort, E.I., Fransen,M.F.,
Offringa, R., Melief, C.J., and Toes, R.E. (2002). CD40 stimulation leads to effec-
tive therapy of CD40(-) tumors through induction of strong systemic cytotoxic T
lymphocyte immunity. Proc. Natl. Acad. Sci. USA 99, 5561–5566.
Wang, D., and Dubois, R.N. (2008). Pro-inflammatory prostaglandins and
progression of colorectal cancer. Cancer Lett. 267, 197–203.
Wang, T., Niu, G., Kortylewski, M., Burdelya, L., Shain, K., Zhang, S., Bhatta-
charya, R., Gabrilovich, D., Heller, R., Coppola, D., et al. (2004). Regulation of
the innate and adaptive immune responses by Stat-3 signaling in tumor cells.
Nat. Med. 10, 48–54.
Welters, M.J., Kenter, G.G., Piersma, S.J., Vloon, A.P., Lowik, M.J., Berends-
van der Meer, D.M., Drijfhout, J.W., Valentijn, A.R., Wafelman, A.R., Oosten-
dorp, J., et al. (2008). Induction of tumor-specific CD4+ andCD8+ T-cell immu-
nity in cervical cancer patients by a human papillomavirus type 16 E6 and E7
long peptides vaccine. Clin. Cancer Res. 14, 178–187.
Welters, M.J., van der Logt, P., van den Eeden, S.J., Kwappenberg, K.M.,
Drijfhout, J.W., Fleuren, G.J., Kenter, G.G., Melief, C.J., van der Burg, S.H.,
and Offringa, R. (2006). Detection of human papillomavirus type 18 E6 and
E7-specific CD4+ T-helper 1 immunity in relation to health versus disease.
Int. J. Cancer 118, 950–956.
Willimsky, G., Czeh,M., Loddenkemper, C., Gellermann, J., Schmidt, K.,Wust,
P., Stein, H., and Blankenstein, T. (2008). Immunogenicity of premalignant
lesions is the primary cause of general cytotoxic T lymphocyte unresponsive-
ness. J. Exp. Med. 205, 1687–1700.
Zang, X., and Allison, J.P. (2007). The B7 family and cancer therapy: Costimu-
lation and coinhibition. Clin. Cancer Res. 13, 5271–5279.
Zeelenberg, I.S., Ostrowski, M., Krumeich, S., Bobrie, A., Jancic, C., Boisson-
nas, A., Delcayre, A., Le Pecq, J.B., Combadiere, B., Amigorena, S., and Thery,
C. (2008). Targeting tumor antigens to secreted membrane vesicles in vivo in-
duces efficient antitumor immune responses. Cancer Res. 68, 1228–1235.
Zhang, B., Bowerman, N.A., Salama, J.K., Schmidt, H., Spiotto, M.T., Schie-
tinger, A., Yu, P., Fu, Y.X., Weichselbaum, R.R., Rowley, D.A., et al. (2007). In-
duced sensitization of tumor stroma leads to eradication of established cancer
by T cells. J. Exp. Med. 204, 49–55.
Zitvogel, L., Apetoh, L., Ghiringhelli, F., and Kroemer, G. (2008). Immunological
aspects of cancer chemotherapy. Nat. Rev. Immunol. 8, 59–73.
Zou, W. (2006). Regulatory T cells, tumour immunity and immunotherapy. Nat.
Rev. Immunol. 6, 295–307.
Zou, W., and Chen, L. (2008). Inhibitory B7-family molecules in the tumour mi-
croenvironment. Nat. Rev. Immunol. 8, 467–477.
Zwaveling, S., Ferreira Mota, S.C., Nouta, J., Johnson, M., Lipford, G.B., Off-
ringa, R., van der Burg, S.H., and Melief, C.J. (2002). Established human pap-
illomavirus type 16-expressing tumors are effectively eradicated following vac-
cination with long peptides. J. Immunol. 169, 350–358.Immunity 29, September 19, 2008 ª2008 Elsevier Inc. 383
